In conclusion, the combination of HDACi with NK cell-based immunotherapy is an attractive treatment option for pancreatic tumors, specifically for patients with high SKI protein levels to overcome SKI-mediated immune evasion. This evidence concerns the gene SKI and pancreatic neoplasm.